BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Immunocore Holdings plc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Immunocore Holdings plc's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06112314-10943@assetmemo.bio
DTSTAMP:20261121T005927Z
DTSTART;VALUE=DATE:20271016
DTEND;VALUE=DATE:20271017
SUMMARY:brenetafusp: Phase 3 readout est. (NCT06112314)
DESCRIPTION:brenetafusp\, phase 3.\nStudy: IMC-F106C Regimen Versus Nivolum
 ab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)\nEst
 imated primary completion: 16 October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenetafusp#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06112314
URL:https://assetmemo.bio/drug/brenetafusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549297-10942@assetmemo.bio
DTSTAMP:20261121T005927Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 3 readout est. (NCT05549297)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 3\, Melanoma.\nStudy: Teben
 tafusp Regimen Versus Investigator's Choice in Previously Treated Advanced
  Melanoma (TEBE-AM)\nEstimated primary completion: March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05549297
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
